The Ultimate Guide to the Cannabis Industry

May 26, 2021

In this guide, CGL’s Cannabis Practice Area Expert, Jennifer Gumer, review the past year and look ahead at some noteworthy trends. As a partner at CGL and our Regulatory and Compliance Practice Lead, Jennifer provides strategic counseling, practical advice, and expert advocacy to clients with production needs. As an Adjunct Professor of Law and Bioethics, she is uniquely qualified to handle all interactions with federal, state, and local regulators who oversee product development, manufacturing, and marketing activities, including the FDA and Local Hemp Regulators.

Prior to joining CGL, Jennifer worked at the international law firm Gibson Dunn and Crutcher for more than six years. The focus of Jennifer’s practice at Gibson was FDA, healthcare, and life sciences matters.

Included in this guide:


Looking at Last Year’s Predictions:

  • Reduced Investor Interest in US Cannabis Markets
  • Regulatory Changes in the Cannabis Market
  • Greater Certainty About the Legal Status of Hemp


New & Noteworthy in 2020

  • UN Removes Cannabis from Schedule IV
  • The FTC’s Operation CBDeceipt
  • Health Warnings Required in California beginning Jan. 3rd


COVID & Cannabis

  • The Pandemic Spurred Warnings from the FTC
  • Cannabis Designated Essential
  • Online Ordering


Legal Status Across North America

  • Five More States Legalize it
  • The State of Cannabis in California
  • A Note About Our Southern Neighbors in Mexico
  • Overproduction in Canada


5 Exciting Predictions for 2021


Download Full Guide >



The materials available at this website are for informational purposes only and not for the purpose of providing legal advice. You should contact your attorney to obtain advice with respect to any particular issue or problem. Use of and access to this website or any of the e-mail links contained within the site do not create an attorney-client relationship between CGL and the user or browser. The opinions expressed at or through this site are the opinions of the individual author and may not reflect the opinions of the firm or any individual attorney.

Other Articles

The 2018 Farm Bill Explained
CBD Brands: 3 Tips for Navigating FDA Law
5 Takeaways for CBD Brands from the Curaleaf FDA Warning Letter

    Ready to Talk?
    Contact Us

    We would to hear from you

    Please take a moment to tell us a few things about your needs and someone from our team will reach out to you as soon as possible.

    We would to hear from you

    Thank you for reaching out!

    Someone from our team will get back to you shortly

    We would to hear from you